Hum. Reprod. Advance Access published online on April 29, 2004
Human Reproduction, doi:10.1093/humrep/deh263
© 2004 by European Society of Human Reproduction and Embryology
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Cholesterol Center, ABC Building, 3200 Burnet Avenue, Cincinnati, OH 45229, USA
* To whom correspondence should be addressed. E-mail: glueckch{at}healthall.com.
BACKGROUND: We prospectively assessed growth and motor-social development during the first 18 months of life in 126 live births (122 pregnancies) to 109 women with polycystic ovary syndrome (PCOS) who conceived on and continued metformin (1.5-2.55 g/day) through pregnancy. METHODS: The lengths and weights of PCOS neonates were compared with gender-specific Centers for Disease Control and Prevention (CDC) infant data. Gestational diabetes (GD) and pre-eclampsia in women with PCOS were compared with 252 healthy women without PCOS who had Key words:
Key words: gestational diabetes/infant development in the first 18 months of life/metformin/pre-eclampsia/polycystic ovary syndrome
Accepted March 23, 2004
Article
Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy
Abstract 
1 live birth (262 live births). RESULTS: There were 101 out of 126 (80%) term (37 gestational weeks) PCOS births, which was not significantly different (P = 0.7) from controls, 206 out of 252 (81.7%). There were two (1.6%) birth defects. GD occurred in nine out of 119 PCOS pregnancies (7.6%) versus 40 out of 251 (15.9%) controls, P = 0.027. The prevalence of pre-eclampsia did not differ in PCOS versus control pregnancies (4.1 versus 3.6%, P = 0.8). The birth length and weight of the 52 male neonates did not differ (P > 0.05) from those of CDC males; the 74 female neonates were shorter than CDC females (48.9 ± 5.4 versus 50.6 ± 2.7 cm, P = 0.006) and weighed less (3.09 ± 0.85 versus 3.29 ± 0.52 kg, P = 0.04). There were no systematic differences in growth between PCOS and CDC infants over 18 months. At 3, 6, 9, 12 and 18 months, of a potential 100% motor-social development score, scores (±SD) were 95 ± 13, 98 ± 8%, 95 ± 10, 97 ± 8 and 94 ± 16%; no infants had motor-social developmental delays. CONCLUSIONS: Metformin reduced development of GD, was not teratogenic and did not adversely affect birth length and weight, growth or motor-social development in the first 18 months of life.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. A Mahmood Influences of excess adiposity on reproductive function The British Journal of Diabetes & Vascular Disease, September 1, 2009; 9(5): 197 - 199. [PDF]
|
|
|
|
|
|
S. L Hyer, J. Balani, A. Johnson, and H. Shehata Metformin treatment for gestational diabetes The British Journal of Diabetes & Vascular Disease, September 1, 2009; 9(5): 220 - 225. [Abstract] [PDF]
|
|
|
|
|
|
S. Teelucksingh and L. M Pinto Pereira Metformin: an important tool for endocrinology in the West Indies. New tricks for an old drug The British Journal of Diabetes & Vascular Disease, September 1, 2009; 9(5): 232 - 236. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S Lindsay Gestational diabetes: causes and consequences The British Journal of Diabetes & Vascular Disease, January 1, 2009; 9(1): 27 - 31. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Rowan, W. M. Hague, W. Gao, M. R. Battin, M. P. Moore, and the MiG Trial Investigators Metformin versus Insulin for the Treatment of Gestational Diabetes N. Engl. J. Med., May 8, 2008; 358(19): 2003 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S Feig, G. G Briggs, and G. Koren Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? Ann. Pharmacother., July 1, 2007; 41(7): 1174 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.M. Boomsma, M.J.C. Eijkemans, E.G. Hughes, G.H.A. Visser, B.C.J.M. Fauser, and N.S. Macklon A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome Hum. Reprod. Update, November 1, 2006; 12(6): 673 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Carlsen, G Jacobsen, and P Romundstad Maternal testosterone levels during pregnancy are associated with offspring size at birth. Eur. J. Endocrinol., August 1, 2006; 155(2): 365 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Brown, J. Wyckoff, J. A. Rowan, L. Jovanovic, D. A. Sacks, and G. G. Briggs Metformin in Pregnancy: Its time has not yet come Diabetes Care, February 1, 2006; 29(2): 485 - 486. [Full Text] [PDF]
|
|
|
|
 |
|
 I. E. Messinis Ovulation induction: a mini review Hum. Reprod., October 1, 2005; 20(10): 2688 - 2697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.A. Checa, A. Requena, C. Salvador, R. Tur, J. Callejo, J.J. Espinos, F. Fabregues, J. Herrero, and (Reproductive Endocrinology Interest Group of the Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2005; 11(4): 375 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Ehrmann Polycystic Ovary Syndrome N. Engl. J. Med., March 24, 2005; 352(12): 1223 - 1236. [Full Text] [PDF]
|
|